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1972Background: The aim of our study was to identify preoperative risk factors affecting overall survival after
cardiac retransplantation (ReTX) in a contemporary era.
Methods: The United Network for Organ Sharing database was used to identify patients undergoing ReTX
between 1995 and 2012. Of the total 28,464 primary transplants performed, 987 (3.5%) were retransplants.
The primary outcome investigated was overall survival. The influence of preoperative donor and recipient char-
acteristics on survival were then tested with univariate logistic regression and multivariate Cox regression
models.
Results: Of 987 patients who underwent ReTX, median survival was 9 years. Estimated survival at 1, 3, 5, 10,
and 15 years following retransplant was 80% (95% confidence interval [CI], 78%-83%), 70% (95% CI,
67%-73%), 64% (95% CI, 61%-67%), 47% (95% CI, 43%-51%), and 30% (95% CI, 25%-37%), respec-
tively. Clinical predictors of survival using multivariable analysis included donor age (relative risk [RR], 1.14;
P ¼ .004), ischemic time>4 hours (RR, 1.48; P ¼ .004); preoperative support with extracorporeal membrane
oxygenator (RR, 3.91; P<.001), and the time between previous and current transplant (P¼ .004). Patients with
ReTX have 1.27 times higher relative risk of death compared with patients undergoing primary transplant only
(RR, 1.27; 95% CI, 1.13-1.42; P<.001).
Conclusions: Patients who undergo cardiac ReTX can expect to have a 1-year survival less than a patient un-
dergoing primary transplant with an acceptable median overall survival. Both donor and recipient preoperative
factors contribute to overall survival following cardiac ReTx. Donor characteristics include age of the donor and
ischemic time. Recipient factors include the need for extracorporeal membrane oxygenator and the number of
days between the first and second transplant. Optimal survival following cardiac ReTX can best be predicted
by choosing patients who are farther out from their initial transplant, not dependent upon preoperative
extracorporeal support, and by choosing donor hearts younger in age and those likely to have shorter ischemic
times. (J Thorac Cardiovasc Surg 2014;147:1972-7)Supplemental material is available online.
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The Journal of Thoracic and Cardiovascular Surtransplant. The International Society for Heart and Lung
Transplantation (ISHLT) estimates the median survival for
primary heart transplants to be 10 years, but little is reported
or known about long-term outcomes or survival in recipi-
ents of ReTx.1 Previous reports have documented 1-year
survival between 23% and 65% following ReTX.2-7 This
fact has led some to conclude that ReTX should be
limited, given the scarcity of suitable cardiac donors.3-8
Our study provides a review of ReTX in the United States
from 1995 through 2012 using data submitted to the
United Network for Organ Sharing (UNOS) database, a
prospectively collected registry that collects voluntary
data from all United States transplant centers. This
analysis focused on evaluation of overall survival
following ReTX and identification of the preoperative
donor and recipient risk factors that determine outcomes.
This analysis is limited to a contemporary cohort of
patients who have undergone cardiac ReTX in the United
States from 1995 to 2012 to provide updated information
on risk factors and overall survival.gery c June 2014
Abbreviations and Acronyms
ECMO ¼ extracorporeal membrane oxygenator
IABP ¼ intra-aortic balloon pump
ISHLT ¼ International Society for Heart and Lung
Transplantation
ReTX ¼ retransplantation
UNOS ¼ United Network for Organ Sharing
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Study Patients and Data Collection
Our review is a retrospective analysis of all 987 patients, at least 18
years of age, from the UNOS database of adult patients who underwent
heart ReTX between 1995 and 2010. Information collected regarding
recipients (ie, age at initiation, age at retransplant, gender, citizenship,
initial body mass index, serum total albumin, ventricular assist device
before retransplant, preoperative dependence on inotropes, ventilator sta-
tus, intra-aortic balloon pump [IABP] status, extracorporeal membrane
oxygenation [ECMO] status, diabetes, and dialysis) and information
regarding donors (age, gender, and left ventricular ejection fraction of
donor hearts). These variables were submitted to univariate analysis. Sig-
nificant factors were then subjected to multivariate analysis.
Statistical Analysis
Continuous variables were summarized with the sample median and
range. Categorical variables were summarized with number and percent-
age. TheKaplan-Meier curve analysis alongwith 95% confidence intervals
(CIs) was used to assess overall survival following ReTX. A single variable
Cox proportional hazards regression model was used to evaluate associa-
tions of recipient and donor characteristics with overall survival following
ReTX; relative risks (RRs) and 95% CIs were estimated. A multivariable
Cox proportional hazards regression model was used to assess if any signif-
icant association of recipient and donor characteristics still hold while con-
trolling for other confounding variables. No adjustment for multiple testing
was made in these exploratory analyses. Statistical analysis was performed
using SAS (version 9.2; SAS Institute, Inc, Cary, NC) and R Statistical
Software (version 2.14.0; R Foundation for Statistical Computing, Vienna,
Austria).T
XRESULTS
A summary of recipient and donor information is dis-
played in Table 1 for the 987 study recipients. Median age
of recipient at retransplant was 50 years (range, 18-74
years). Recipients requiring mechanical circulatory support
before ReTX included 38 patients (3.9%). Most of the re-
cipients were men (71%) and US citizens (99%). The me-
dian initial body mass index of recipients was 25.9 (range,
12.3-50.7). The majority of patients (63%) had serum total
albumin 3. Twenty-six recipients (3%) were receiving
ECMO, 58 (6%) had an IABP, 74 (7.5%) required venti-
lator support, and a total of 474 (48%) required inotropic
support before transplant. Two hundred twenty-four
(23%) recipients had type 1 or type 2 diabetes diagnosed
before transplant and 112 (11.5%) were receiving hemo-
or peritoneal dialysis before transplant.The Journal of Thoracic and CarThe median donor age was 30 years (range, 9-63 years),
and 66% donors were men. Almost all donor hearts (97%)
had left a ventricular ejection fraction of 50% or more. The
median ischemic time was 3.3 hours (range, 1.0-9.2 hours).
The distribution of number of retransplant procedures in the
United States from 1995 to 2012 is given in Table 2. The
range of number of retransplants was 40 to 71; the lowest
number of retransplants occurred during 1997 and the high-
est during 2011. The distribution of retransplants by region
is listed in Appendix Table E1.
The median follow-up length was 3.1 years (range,
0-17.1 years), and a total of 426 patients (43%) died during
follow-up. Estimated survival at 1, 3, 5, 10, and 15 years
following retransplant was 80% (95% CI, 78%-83%),
70% (95% CI, 67%-73%), 64% (95% CI, 61%-67%),
47% (95% CI, 43%-51%), and 30% (95% CI,
25%-37%), respectively (Table 3 and Figure 1). Associa-
tions of survival with recipients and donor characteristics
in univariate and multivariate analysis are displayed in
Table 4. With the multivariable Cox regression analysis,
recipient characteristics associated with increased risk of
death included support with ECMO (RR, 3.91; P<.001),
and time between previous transplant and current transplant
(P¼ .004) (Figure 2). Donor characteristics associated with
increased risk of death included age (RR, 1.14; P ¼ .004)
and ischemic time (RR, 1.48; P ¼ .004). Although univari-
ate analysis demonstrated that the age of recipient at trans-
plant, total serum albumin, need for mechanical ventilation,
and presence of IABP had shown significant association
with survival, these variables did not meet statistical signif-
icance in the multivariate analysis. In comparison with the
ReTx patients>1 year from primary transplant versus those
receiving primary transplants during the same period,
ReTX patients have 1.27 times higher RR of death
compared with patients with primary transplant only
(RR, 1.27; 95% CI, 1.13-1.42; P<.001) (Figure 3).
DISCUSSION
ReTX has remained controversial since the first reports
more than 30 years ago.8 This was primarily due to the
shortage of suitable donors for cardiac transplantation.
Currently, 400 patients die every year waiting for a suitable
donor heart. The lack of suitable donor hearts, in addition to
the poor outcomes historically associated with ReTX, has
led several authors to conclude that the practice of cardiac
ReTX poses an ethical dilemma and should therefore be
limited.9-14 Survival following ReTX during the 1970s
and the early 1990s was particularly poor in patients
receiving retransplant within 1 month of the first
transplant.5,6,15
Because reports of ReTX emerged from the ISHLT dur-
ing the early 1990s showing that the 1-year survival
following ReTX was only 42%, some members of the
European community believed that ReTX should not bediovascular Surgery c Volume 147, Number 6 1973
TABLE 1. Recipient and donor characteristics
Variable*
Overall sample
(N ¼ 987)
Age at retransplant (y) 50 (18-74)
Age at initiation (y) 49 (15-73)
Sex (male) 697 (70.6)
US citizenship 973 (99)
Initial BMI 25.9 (12.3-50.7)
Acute rejection episodes
1 41 (7.7)
2 30 (5.6)
3 464 (86.7)
Graft failure cause
Hyper acute rejection 26 (35.1)
Acute rejection 12 (16.2)
Chronic rejection 21 (28.4)
Unknown 15 (20.3)
Days listed as status 1 0 (0-224)
Days listed as status 1a 0 (0-692)
Days listed as status 1b 0 (0-1904)
Days listed as status 2 14 (0-2491)
Ischemic time (h) 3.3 (1.0-9.2)
Length of hospital stay (d) 2 (0-9)
Serum total albumin
3 391 (63.0)
>3 230 (37.0)
VAD before transplant 38 (3.9)
Cardiac output obtained while on inotropes 176 (22.3)
Inotropes 474 (48.0)
Ventilator 74 (7.5)
IABP 58 (5.9)
ECMO 26 (2.6)
Diabetes
Type 1 23 (2.4)
Type 2 81 (8.3)
Unknown 120 (12.3)
Dialysis at listing
Hemodialysis 69 (7.1)
Peritoneal dialysis 4 (0.4)
Unknown 39 (4.0)
Donor age (y) 30 (9-63)
Donor sex (male) 654 (66.3)
Left ventricular ejection fraction of donor heart (%)
30 4 (0.5)
40 16 (2.2)
50 719 (97.3)
The sample median (range) is given for continuous variables and number (percent) is
given for categorical variables. BMI, Body-mass index; VAD, ventricular assist de-
vice; IABP, intra-aortic balloon pump; ECMO, extracorporeal membrane oxygena-
tion. *Information was not available for the following variables: citizenship
(n ¼ 4), initial BMI (n ¼ 30) acute rejection episodes (n ¼ 452), ischemic time
(n ¼ 79), length of stay (n ¼ 254), graft failure cause (n ¼913), left ventricular ejec-
tion fraction of donor heart (n ¼ 248), serum total albumin (n ¼ 366), cardiac output
obtained while on inotropes (n ¼ 196), diabetes (n ¼ 11), and dialysis at listing
(n ¼ 11).
TABLE 2. Number of retransplants, by year
Year of
retransplant
Retransplant
sample (N ¼ 987)
Proportion of total heart
transplants in United States
1995 47 (4.8) 47/2363 (2.0)
1996 44 (4.5) 44/2343 (1.9)
1997 40 (4.1) 40/2293 (1.7)
1998 67 (6.8) 67/2348 (2.9)
1999 55 (5.6) 55/2188 (2.5)
2000 42 (4.3) 42/2199 (1.9)
2001 49 (5.0) 49/2202 (2.2)
2002 51 (5.2) 51/2155 (2.4)
2003 42 (4.3) 42/2057 (2.0)
2004 51 (5.2) 51/2015 (2.5)
2005 64 (6.5) 64/2125 (3.0)
2006 53 (5.4) 53/2193 (2.4)
2007 60 (6.1) 60/2209 (2.7)
2008 64 (6.5) 64/2163 (3.0)
2009 60 (6.1) 60/2211 (2.7)
2010 67 (6.8) 67/2332 (2.9)
2011 71 (7.2) 71/2322 (3.1)
2012 60 (6.1) 60/2378 (2.5)
Values are given as n (%).
TABLE 3. Survival following retransplant procedure
Length of time after
retransplant (y) Proportion of survival (95% CI)
1 80 (78-83)
2 75 (72-78)
3 70 (67-73)
4 68 (65-71)
5 64 (61-67)
6 60 (57-64)
7 56 (53-60)
8 54 (50-58)
9 50 (46-54)
10 47 (43-51)
11 44 (40-48)
12 41 (37-46)
13 38 (33-43)
14 36 (31-41)
15 30 (25-37)
Values are given as%. CI, Confidence interval.
Cardiothoracic Transplantation Belli et al
T
Xperformed at all.13 A single center from France (Schnetzler
and colleagues5) reported on 24 patients undergoing re-
transplant compared with 47 patients undergoing primary1974 The Journal of Thoracic and Cardiovascular Surtransplant as controls. Survival at 1 and 5 years for ReTX
were 45.5% and 31.2%, respectively, compared with
59.4% and 38.8% for controls.5 In another report16
comparing the survival of patients undergoing retransplant
at a single US institution compared with data from the
ISHLT, survival was found to be as high as 64% at 1
year, provided that certain criteria were met. They identified
the ‘‘ideal candidate’’ for ReTX as a patient who had an in-
terval between transplants>6 months, a date of second
operation after 1985, and without preoperative mechanical
support.16 Despite these attempts to refine the criteria for
ReTX, many centers still refused to adopt this practice.gery c June 2014
FIGURE 1. Survival following retransplantation. Dashed lines represent 95% confidence intervals.
Belli et al Cardiothoracic TransplantationMore recent data have shown improved survival
following ReTX. Srivastava and colleagues,6 using ISHLT
registry data from 1987 through 1998, reported a 65%
1-year survival for 514 patients undergoing ReTX. Another
important conclusion from that study was that overall sur-
vival following ReTX approached that of primary transplant
if the interval between transplants was>2 years. These con-
clusions, however, were only valid for centers performing at
least 9 heart transplants per year and for patients who were
not dependant on a ventilator or a left ventricular assist
device.
The data presented in our study are unique in that the pop-
ulation studied represents a large sample of patients under-
going ReTX subject to contemporary selection processes,TABLE 4. Associations of recipient and donor characteristics with overall
Variable
Singl
RR (95%
Age at retransplant (10-y increase) 1.08 (1.01-
Gender (male) 0.85 (0.69-
Donor age (10-y increase) 1.11 (1.03-
Time between previous transplant and retransplant (y)y
1 1.00 (refere
>1  5 0.54 (0.38-
>5 0.43 (0.32-
Ischemic time (>4 h) 1.52 (1.20-
Serum total albumin (>3) 0.71 (0.54-
Inotropes 1.14 (0.95-
Ventilator 2.44 (1.81-
IABP 1.86 (1.32-
ECMO 5.68 (3.60-
Diabetes 1.21 (0.97-
Dialysis at listing 1.43 (1.09-
RR, Relative risk; CI, confidence interval; NI, not included in the multivariable analysis; N/
oxygenation. *RRs, 95% CIs, and P values result from Cox proportional hazards regression
variables) or the increase given in parenthesis (continuous variables). All variables with
(n ¼ 797), except serum total albumin because of the large amount of missing informatio
analysis: P<.001. Test of overall difference for multivariable analysis: P ¼ .003.
The Journal of Thoracic and Carsurgical techniques, and methodology that therefore pro-
vides a unique perspective on patients undergoing ReTX.
In our large cohort, survival at 1, 3, and 5 years was 80%,
70%, and 64%, respectively, which is significantly higher
than that previously published. The reasons for improved
survival have not yet been clearly elucidated; however,
more refined retransplant candidate screening selection pro-
cesses; improvement in surgical and perioperative tech-
niques; and better posttransplant medical protocols,
including advances in immunosuppressive therapy, all serve
as potential explanations.
Previously published studies have shown that preopera-
tive mechanical ventilation, high serum creatinine, and
older recipient age are associated with poorer graftsurvival following retransplant*
e variable analysis Multivariable analysis
CI) P value RR (95% CI) P value
1.15) .034 1.08 (0.99-1.17) .072
1.04) .12 NI N/A
1.20) .004 1.14 (1.05-1.25) .004
nce) N/A 1.00 (reference) N/A
0.75) <.001 0.66 (0.44-1.01) .053
0.58) <.001 0.53 (0.36-0.78) .001
1.92) <.001 1.48 (1.12-1.87) .004
0.94) .017 NI N/A
1.38) .17 NI N/A
3.29) <.001 1.29 (0.82-2.03) .27
2.63) <.001 1.03 (0.66-1.60) .90
8.97) <.001 3.91 (2.08-7.38) <.001
1.51) .092 NI N/A
1.90) .011 1.12 (0.77-1.63) .56
A, not applicable; IABP, intra-aortic balloon pump; ECMO, extracorporeal membrane
models. Relative risks correspond to presence of the given characteristic (categorical
P value  .05 in a single variable analysis were included in multivariable analysis
n (missing ¼ 366) with this variable. yTest of overall difference for single-variable
diovascular Surgery c Volume 147, Number 6 1975
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FIGURE 2. Survival following retransplantation according to the time between previous transplant and retransplant.
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Xsurvival.17 The data from our study emphasize both donor
and recipient risk factors. Univariate analysis showed that
donor age; recipient age; days between first transplant and
ReTX; serum albumin; ventilator status; and pretransplant
dependence on IABP, ECMO, or dialysis were significant
predictors of outcome.
Regarding recipient risk factors for decreased survival
following ReTX, further stratification with multivariate
analysis demonstrated reduced survival for recipients
requiring pretransplant ECMO and those having had a
shorter time between transplants. Patients who received
an immediate transplant for primary graft failure had a
much worse prognosis than those who had an indolent
course of chronic heart failure with a longer time course af-
ter their initial transplant. Although current guidelines from
the American Society of Transplant Surgeons suggest the
interval between transplants be at least 6 months,3 data
from our study suggest that optimal survival following
ReTX occurs when the interval between the initial trans-
plant and retransplant is at least 1 year, with at least 5 yearsFIGURE 3. Survival following retransplantation (ReTX)>1
1976 The Journal of Thoracic and Cardiovascular Surbeing the optimal interval. According to the data reported in
our study, dependence on ECMO before transplant confers
a dismal prognosis and therefore should serve as a relative
contraindication to ReTX. Mechanical support with
ECMO was the strongest RR factor for decreased survival.
Contrary to previously published reports, recipient factors
not found to be statistically significant included pretrans-
plant ventilator status and dependence on inotropic support.
The majority of patients undergoing ReTX were, in fact,
treated with inotropes without a significant effect on overall
patient survival following transplant.
Donor factors significant for reduced survival after ReTX
by multivariate analysis included the donor heart age and
total ischemic time after harvest.
In the current era, the annual number of ReTX procedures
reported in the United States consistently represents 2% to
3% of all transplants. These data were obtained from the
UNOS database, which is not an audited registry. Because
these data are obtained and reported voluntarily, all out-
comes data regarding patients undergoing ReTX may notyear from primary transplant (TX) versus primary TX.
gery c June 2014
Belli et al Cardiothoracic Transplantationhave been captured, which serves as an important limitation
of our study.
Despite this limitation, our study does allow us to draw
several important conclusions regarding improved survival
following ReTX that contradicts historical data and pub-
lished guidelines. Most notably, patients who have survived
at least 1 year from the primary transplant have better over-
all survival compared with those who are<1 year out from
their initial surgery. Patients surviving at least 5 years from
their initial transplant had optimal survival following
ReTX. The reason for the improved survival observed
following ReTX in our study is likely multifactorial. The
reasons for this positive change may be related to improve-
ments in modern therapy, improved immunosuppressive
regimens, and/or better selection of retransplant candidates.
Nevertheless, patients undergoing ReTX even 1 year from
primary transplant continue to have a lower overall survival
compared with primary transplants in the same era. The dif-
ference may be less than anticipated by transplant centers.
CONCLUSIONS
ReTX remains a viable option for a limited transplant
population. Optimal candidates for consideration of ReTX
include younger recipients who are at least 1 year out
from their primary transplant. ECMO before ReTX is the
strongest negative predictor of overall survival and should
therefore be considered a relative contraindication to
ReTX. Inotropic support before ReTX has no effect on
overall survival and should not preclude a patient from
ReTX. Cardiac ReTX continues to grow as a viable option
for transplant recipients with primary graft failure.
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APPENDIX TABLE E1. Distribution of patients by US regions and
US states and territories
Region, state,* or territory Overall sample (N ¼ 987)
US region
1 29 (2.9)
2 131 (13.3)
3 136 (13.8)
4 93 (9.4)
5 233 (23.6)
6 25 (2.5)
7 70 (7.1)
8 70 (7.1)
9 76 (7.7)
10 69 (7.0)
11 55 (5.6)
US state or territory
Alaska 1 (0.1)
Alabama 13 (1.3)
Arkansas 15 (1.5)
Arizona 13 (1.3)
California 187 (19.1)
Colorado 29 (3)
Connecticut 10 (1)
Washington, DC 1 (0.1)
Delaware 5 (0.5)
Florida 61 (6.2)
Georgia 25 (2.6)
Hawaii 1 (0.1)
Iowa 7 (0.7)
Idaho 6 (0.6)
Illinois 28 (2.9)
Indiana 28 (2.9)
Kansas 13 (1.3)
Kentucky 7 (0.7)
Louisiana 16 (1.6)
Massachusetts 11 (1.1)
Maryland 22 (2.3)
Maine 2 (0.2)
Michigan 18 (1.8)
Minnesota 16 (1.6)
Missouri 13 (1.3)
Mississippi 9 (0.9)
Montana 4 (0.4)
North Carolina 27 (2.8)
North Dakota 1 (0.1)
Nebraska 6 (0.6)
New Hampshire 3 (0.3)
New Jersey 56 (5.7)
New Mexico 3 (0.3)
Nevada 2 (0.2)
New York 58 (5.9)
Ohio 24 (2.5)
Oklahoma 6 (0.6)
Oregon 9 (0.9)
Pennsylvania 48 (4.9)
Puerto Rico 6 (0.6)
Rhode Island 3 (0.3)
(Continued)
APPENDIX TABLE E1. Continued
Region, state,* or territory Overall sample (N ¼ 987)
South Carolina 10 (1)
South Dakota 1 (0.1)
Tennessee 15 (1.5)
Texas 81 (8.3)
Utah 12 (1.2)
Virginia 6 (0.6)
Vermont 2 (0.2)
Washington 13 (1.3)
Wisconsin 21 (2.2)
West Virgina 2 (0.2)
Wyoming 1 (0.1)
Values are given as n (%). *Missing information: States (n ¼ 10).
Cardiothoracic Transplantation Belli et al
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